KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Share-based Compensation (2016 - 2025)

CRISPR Therapeutics AG's Share-based Compensation history spans 11 years, with the latest figure at $18.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 17.64% year-over-year to $18.1 million; the TTM value through Dec 2025 reached $72.5 million, down 16.25%, while the annual FY2025 figure was $72.5 million, 16.25% down from the prior year.
  • Share-based Compensation for Q4 2025 was $18.1 million at CRISPR Therapeutics AG, up from $16.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $28.3 million in Q2 2021 and bottomed at $16.6 million in Q3 2025.
  • The 5-year median for Share-based Compensation is $21.9 million (2023), against an average of $22.0 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 80.49% in 2021 before it dropped 25.62% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $25.8 million in 2021, then decreased by 11.53% to $22.8 million in 2022, then fell by 19.23% to $18.4 million in 2023, then increased by 19.15% to $21.9 million in 2024, then fell by 17.64% to $18.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Share-based Compensation are $18.1 million (Q4 2025), $16.6 million (Q3 2025), and $17.6 million (Q2 2025).